HLAG antibody

Catalog No. ABIN2689559

Product Details anti-HLAG Antibody

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This HLAG antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Brand: BD Pharmingen™

Characteristics: HLA-G is a HLA class I molecule, but it is distinct from other class I molecules because of its quasi-monomorphism and restricted tissue distribution. It can be expressed as seven distinct protein forms. HLA-G1, -G2, G3, and -G4 are membrane bound while HLA-G5, -G6, and G7 are soluble. HLA-G is expressed in healthy individuals on amniocytes and cytotrophoblasts in the amnion-chorion. HLA-G interacts with inhibitory receptors such as ILT-2, ILT-4, p49 and KIR2DL4 expressed on NK cells, shifts the cytokine balance towards Th2 dominance, suppresses the proliferation of allogeneic CD4 lymphocytes and, in its soluble form, induces apoptosis of activated CD8 cells and inhibits cytolysis by NK cells. This antibody is routinely tested by flow cytometric analysis. Other applications were tested during antibody development only or reported in the literature. Profile of human HLA-G (denatured) reactivity on fixed, permeabilized JEG-3 cell line analyzed by flow cytometry. Fixed and permeabilized with Cat. No. 554714. Second step staining with Cat. No. 555988.

BD Pharmingen™ Purified Mouse Anti-human HLA-G Denatured - Purified - Clone 4H84 - Isotype Mouse IgG1, κ - Reactivity Hu - 0.1 mg

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: human HLA-G Denatured

Clone: 4H84

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store undiluted at 4°C.

References for anti-HLAG antibody (ABIN2689559)

Dorling, Monk, Lechler: "HLA-G inhibits the transendothelial migration of human NK cells." in: European journal of immunology, Vol. 30, Issue 2, pp. 586-93, (2000) (PubMed).

King, Allan, Bowen, Powis, Joseph, Verma, Hiby, McMichael, Loke, Braud: "HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells." in: European journal of immunology, Vol. 30, Issue 6, pp. 1623-31, (2000) (PubMed).

Le Bouteiller, Blaschitz: "The functionality of HLA-G is emerging." in: Immunological reviews, Vol. 167, pp. 233-44, (1999) (PubMed).

Le Bouteiller, Solier, Pröll, Aguerre-Girr, Fournel, Lenfant: "Placental HLA-G protein expression in vivo: where and what for?" in: Human reproduction update, Vol. 5, Issue 3, pp. 223-33, (1999) (PubMed).

Le Gal, Riteau, Sedlik, Khalil-Daher, Menier, Dausset, Guillet, Carosella, Rouas-Freiss: "HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes." in: International immunology, Vol. 11, Issue 8, pp. 1351-6, (1999) (PubMed).

McMaster, Zhou, Shorter, Kapasi, Geraghty, Lim, Fisher: "HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 160, Issue 12, pp. 5922-8, (1998) (PubMed).

Target Details for HLAG

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Alternative Name: HLA-G (HLAG Products)

Synonyms: MHC-G antibody, B-F antibody, B-F-S04 antibody, B-F-S05 antibody, B-F-S06 antibody, B-F-S07 antibody, B-FI antibody, B-FIV antibody, BF2 antibody, BFa2 antibody, BFw-03 antibody, BFw-05 antibody, BFz-01 antibody, major histocompatibility complex, class I, G antibody, MHC BF1 class I antibody, HLA-G antibody, BF1 antibody

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints